Partnering
Hu-PAC™ and Retrocyte Display™ are unencumbered novel and synergistic therapeutic antibody discovery platforms
The Hu-PAC™ and Retrocyte Display™ platforms are unencumbered by patent or licensing restrictions and can be used to develop antibodies against any antigen target.
The following partnering options are available with 4-Antibody:
- Out-licensing or partnered development of Hu-PAC™ and Retrocyte Display™ developed fully human antibodies from the 4-Antibody discovery pipeline.
- Joint therapeutic antibody co-development projects for validated targets.
- Non-exclusive licensing of the Hu-PAC™ and Retrocyte Display™ antibody discovery platforms for in-house discovery of programs against any target.